Ventas Inc (VTR)

$79.10 +0.06 (0.08%)
Market Cap 38.96B
Revenue (ttm) 5.83B
Net Income (ttm) 251.38M
EPS (ttm) N/A
PE Ratio 22.38
Forward PE 20.67
Profit Margin 4.31%
Debt to Equity Ratio 0.95
Volume 3,013,400
Avg Vol 4,218,078
Day's Range N/A - N/A
Shares Out 486.17M
Stochastic %K 9%
Beta 0.71
Analysts Strong Sell
Price Target $97.10

Company Profile

Ventas, Inc. is a leading S&P 500 real estate investment trust enabling exceptional environments that benefit a large and growing aging population. With approximately 1,400 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy. The Company's growth is fueled by its more than 850 senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments. Ventas aims to deliver outsized perfo...

Industry: REIT - Healthcare Facilities
Sector: Real Estate
Phone: 877 483 6827
Address:
300 North LaSalle Street, Suite 1600, Chicago, United States
Bobby_Six_killer
Bobby_Six_killer Jun. 4 at 10:31 PM
$LXRX $NVO $VTR curious why you state "ever expanding sales of inpefa"? 2025 Q1 sales were 1.3 million, while 2026 Q1 sales were 1.1 million. Go back to Q4 2024, net sales were 1.6 million. Are you aware inpefa sales are actually contracting? And you have the audacity to brag in point A, that Inpefa for HCM "is OURS no partnerships". I know you are new to this company, so maybe you aren't aware, but LXRX disbanded their entire sales department in late 2024. So no sales department, they've halted all marketing for Inpefa, so how exactly do you plan to sell if if approved? Hint, it involves finding a partner. And you think drug companies involved with diabetes are going to line up to partner on Sota for T1D after the FDA rejected 3 times already? Take off the rose colored pumper glasses, and realize if pilavapadin fails to meet it's Phase 3 endpoint like it did already for Phase 2, this company is dead in the water.
0 · Reply
SniperPro
SniperPro Jun. 4 at 6:50 PM
$LXRX $NVO $VTR Pretty good summary. HCM still hasn't fully decided yet. I bet they want to test the waters, but they need to stop dealing with the same BS. They need to focus on R&D and selling/partnering assets—nothing else. Collect royalties and keep it simple. Money Money MOneyyyyyyyyy 🤑 🤑 🤑
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 4 at 6:43 PM
$LXRX For those confused on what he said on Pilavapadin Partnership, he said, that big interested parties, came with an offer of large sums, JUST on the Phase 3 results. No need to commit and hang our IP to them until then. Better value for LXRX to hold on to our IP fully, I talked about this before here. It's exactly what he talked about right now. A. HCM will be fully OURS no partnerships. B. Zotagliflozin Type 1 we can partner with many deeply in the Diabetes 1 arena. No other alternative other than insulin for these poor people. C. Novo will dole out another 60 mil by appx on upcoming data from Phase trial studies. They featured it in their last Qtrly $NVO did. D. $VTR will be supplying revenues on an ever expanding sales of Inpefa.
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jun. 3 at 1:07 AM
📊 $VTR Elliott Wave Analysis 🚀 Bullish trend unfolding with upside targets at 104 and beyond — full breakdown available now! 👉 Read here: https://elliottwave-forecast.com/stock-market/ventas-vtr-elliott-wave-analysis-target-104-bullish-trend/ #VTR #ElliottWave #Stocks #Trading #Markets
0 · Reply
PrnceMichael
PrnceMichael Jun. 2 at 4:58 PM
$GOAI #Nasdaq Alert -EVA Live (Nasdaq: GOAI) signed a Letter of Intent with Dermatech Mobile Care, doing business as Spiro Senior Care, for a strategic partnership giving EVA Live a proposed 25% equity stake in the Spiro Senior venture. EVA Live plans to invest up to $20 million in cash, assets and resources to scale Spiro’s AI-driven senior care platform, launched with Meridian Senior Living and its first four senior healthcare facilities, targeting the rapidly growing global geriatric and long-term care markets. https://www.stocktitan.net/news/GOAI/eva-live-targets-the-1-3-trillion-senior-care-industry-through-wkh5mhlcqsh7.html @EvaLiveInc1 @Nasdaq $WELL $VTR
0 · Reply
jbhogan
jbhogan May. 27 at 5:04 PM
$VTR Just mentioned as a buy on CNBC Final Trades. ( Jenny )
0 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 27 at 3:37 AM
📊 $VTR Elliott Wave Analysis 🚀 Bullish trend unfolding with upside targets at 104 and beyond — full breakdown available now! 👉 Read here: https://elliottwave-forecast.com/stock-market/ventas-vtr-elliott-wave-analysis-target-104-bullish-trend/ #VTR #ElliottWave #Stocks #Trading #Markets
0 · Reply
Ares77manoe
Ares77manoe May. 26 at 1:19 PM
$VTR why I sold 3 years ago...
0 · Reply
BillionerOfKing
BillionerOfKing May. 25 at 9:28 PM
$VTR Current Stock Price: $88.18 Contracts to trade: $87.5 VTR Jun 18 2026 Call Entry: $2.20 Exit: $3.65 ROI: 66% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 21 at 2:46 AM
📊 $VTR Elliott Wave Analysis 🚀 Bullish trend unfolding with upside targets at 104 and beyond — full breakdown available now! 👉 Read here: https://elliottwave-forecast.com/stock-market/ventas-vtr-elliott-wave-analysis-target-104-bullish-trend/ #VTR #ElliottWave #Stocks #Trading #Markets
0 · Reply
Latest News on VTR
Ventas Chairman and CEO Debra A. Cafaro to Receive Cyrus McCormick Making History Award for Historic Corporate Achievement

Jun 3, 2026, 4:21 PM EDT - 1 day ago

Ventas Chairman and CEO Debra A. Cafaro to Receive Cyrus McCormick Making History Award for Historic Corporate Achievement

Ventas affirms FY26 FFO view of $3.82-$3.89, consensus $3.87

2026-06-01T20:25:26.000Z - 3 days ago

Ventas affirms FY26 FFO view of $3.82-$3.89, consensus $3.87

Ventas Issues Business Update and Will Participate in Investor Meetings at Nareit's REITweek 2026 Investor Conference

Jun 1, 2026, 4:15 PM EDT - 3 days ago

Ventas Issues Business Update and Will Participate in Investor Meetings at Nareit's REITweek 2026 Investor Conference

Ventas Slides: Investor presentation

Jun 1, 2026, 7:00 AM EDT - 3 days ago

Ventas Slides: Investor presentation

Ventas price target raised to $110 from $102 at BofA

2026-05-26T10:50:49.000Z - 9 days ago

Ventas price target raised to $110 from $102 at BofA

Ventas price target raised to $95 from $93 at Scotiabank

2026-05-21T14:12:05.000Z - 14 days ago

Ventas price target raised to $95 from $93 at Scotiabank

Ventas price target raised to $110 from $100 at Goldman Sachs

2026-05-19T11:12:20.000Z - 16 days ago

Ventas price target raised to $110 from $100 at Goldman Sachs

Ventas Declares Quarterly Dividend of $0.52 Per Common Share

May 13, 2026, 4:30 PM EDT - 22 days ago

Ventas Declares Quarterly Dividend of $0.52 Per Common Share

Ventas Transcript: AGM 2026

May 13, 2026, 9:00 AM EDT - 22 days ago

Ventas Transcript: AGM 2026

Ventas price target raised to $100 from $97 at Jefferies

2026-05-12T21:16:39.000Z - 23 days ago

Ventas price target raised to $100 from $97 at Jefferies

Ventas price target raised to $94 from $93 at JPMorgan

2026-05-11T13:39:15.000Z - 24 days ago

Ventas price target raised to $94 from $93 at JPMorgan

Ventas price target raised to $95 from $90 at KeyBanc

2026-05-07T12:57:27.000Z - 4 weeks ago

Ventas price target raised to $95 from $90 at KeyBanc

Ventas price target raised to $100 from $93 at BMO Capital

2026-05-04T12:47:34.000Z - 4 weeks ago

Ventas price target raised to $100 from $93 at BMO Capital

Ventas price target raised to $98 from $91 at RBC Capital

2026-05-04T11:36:04.000Z - 4 weeks ago

Ventas price target raised to $98 from $91 at RBC Capital

Ventas price target raised to $93 from $85 at UBS

2026-05-04T09:55:09.000Z - 4 weeks ago

Ventas price target raised to $93 from $85 at UBS

Ventas price target raised to $100 from $96 at Citi

2026-05-01T10:57:46.000Z - 4 weeks ago

Ventas price target raised to $100 from $96 at Citi

Ventas price target raised to $95 from $94 at Evercore ISI

2026-04-29T14:43:46.000Z - 5 weeks ago

Ventas price target raised to $95 from $94 at Evercore ISI

Ventas Earnings Call Transcript: Q1 2026

Apr 28, 2026, 10:00 AM EDT - 5 weeks ago

Ventas Earnings Call Transcript: Q1 2026

Ventas Slides: Q1 2026

Apr 28, 2026, 10:00 AM EDT - 5 weeks ago

Ventas Slides: Q1 2026

Ventas Earnings release: Q1 2026

Apr 28, 2026, 10:00 AM EDT - 5 weeks ago

Ventas Earnings release: Q1 2026

Ventas Quarterly report: Q1 2026

Apr 28, 2026, 10:00 AM EDT - 5 weeks ago

Ventas Quarterly report: Q1 2026

Ventas reports Q1 normalized FFO 94c, consensus 91c

2026-04-27T20:32:50.000Z - 5 weeks ago

Ventas reports Q1 normalized FFO 94c, consensus 91c

Ventas raises FY26 normalized FFO midpoint view to $3.86 from $3.83

2026-04-27T20:30:40.000Z - 5 weeks ago

Ventas raises FY26 normalized FFO midpoint view to $3.86 from $3.83

Ventas Reports 2026 First Quarter Results

Apr 27, 2026, 4:10 PM EDT - 5 weeks ago

Ventas Reports 2026 First Quarter Results

Ventas price target raised to $95 from $90 at Deutsche Bank

2026-04-13T12:50:07.000Z - 7 weeks ago

Ventas price target raised to $95 from $90 at Deutsche Bank

Ventas Announces First Quarter 2026 Earnings Release Date and Conference Call

Apr 2, 2026, 4:15 PM EDT - 2 months ago

Ventas Announces First Quarter 2026 Earnings Release Date and Conference Call

Ventas Proxy statement: Proxy filing

Apr 1, 2026, 8:00 AM EDT - 2 months ago

Ventas Proxy statement: Proxy filing

Ventas Proxy statement: Proxy filing

Apr 1, 2026, 8:00 AM EDT - 2 months ago

Ventas Proxy statement: Proxy filing

Ventas price target raised to $93 from $88 at Wells Fargo

2026-03-26T10:27:40.000Z - 2 months ago

Ventas price target raised to $93 from $88 at Wells Fargo

Ventas price target raised to $93 from $88 at JPMorgan

2026-03-20T11:42:22.000Z - 2 months ago

Ventas price target raised to $93 from $88 at JPMorgan

Ventas Stock (VTR) Rides the ‘Gray Wave’ with a Strong Dividend — I’m Bullish

2026-03-19T13:34:14.000Z - 2 months ago

Ventas Stock (VTR) Rides the ‘Gray Wave’ with a Strong Dividend — I’m Bullish

Ventas Transcript: 47th Annual Raymond James Institutional Investor Conference

Mar 4, 2026, 10:25 AM EST - 3 months ago

Ventas Transcript: 47th Annual Raymond James Institutional Investor Conference

Ventas price target raised to $94 from $87 at Mizuho

2026-03-04T12:07:03.000Z - 3 months ago

Ventas price target raised to $94 from $87 at Mizuho

Ventas Transcript: Citi’s Miami Global Property CEO Conference 2026

Mar 3, 2026, 2:55 PM EST - 3 months ago

Ventas Transcript: Citi’s Miami Global Property CEO Conference 2026

Ventas Issues Investor Presentation for Upcoming Investor Conferences

Mar 2, 2026, 7:30 AM EST - 3 months ago

Ventas Issues Investor Presentation for Upcoming Investor Conferences

Ventas Slides: Investor presentation

Mar 2, 2026, 7:00 AM EST - 3 months ago

Ventas Slides: Investor presentation

Ventas Earnings Call Transcript: Q4 2025

Feb 6, 2026, 10:00 AM EST - 4 months ago

Ventas Earnings Call Transcript: Q4 2025

Ventas Annual report: Q4 2025

Feb 6, 2026, 10:00 AM EST - 4 months ago

Ventas Annual report: Q4 2025

Ventas Earnings release: Q4 2025

Feb 6, 2026, 10:00 AM EST - 4 months ago

Ventas Earnings release: Q4 2025

Ventas Slides: Q4 2025

Feb 6, 2026, 10:00 AM EST - 4 months ago

Ventas Slides: Q4 2025

Ventas Reports Fourth Quarter and Full Year 2025 Results, Provides 2026 Outlook and Increases Dividend

Feb 5, 2026, 4:10 PM EST - 4 months ago

Ventas Reports Fourth Quarter and Full Year 2025 Results, Provides 2026 Outlook and Increases Dividend

Ventas Announces Tax Treatment of 2025 Distributions

Jan 20, 2026, 6:18 PM EST - 4 months ago

Ventas Announces Tax Treatment of 2025 Distributions

Ventas Announces Fourth Quarter 2025 Earnings Release Date and Conference Call

Jan 14, 2026, 4:15 PM EST - 5 months ago

Ventas Announces Fourth Quarter 2025 Earnings Release Date and Conference Call

Ventas Declares Quarterly Dividend of $0.48 Per Common Share

Dec 10, 2025, 4:55 PM EST - 6 months ago

Ventas Declares Quarterly Dividend of $0.48 Per Common Share

Ventas to Participate in Investor Meetings at Nareit's REITworld 2025 Annual Conference

Dec 5, 2025, 5:08 PM EST - 6 months ago

Ventas to Participate in Investor Meetings at Nareit's REITworld 2025 Annual Conference

Ventas Announces Pricing of Senior Notes Offering

Dec 2, 2025, 5:11 PM EST - 6 months ago

Ventas Announces Pricing of Senior Notes Offering

Ventas Announces Planned Retirement of Peter J. Bulgarelli, EVP, Outpatient Medical & Research and CEO of Lillibridge Healthcare Services

Nov 17, 2025, 8:00 AM EST - 7 months ago

Ventas Announces Planned Retirement of Peter J. Bulgarelli, EVP, Outpatient Medical & Research and CEO of Lillibridge Healthcare Services

Ventas Earnings Call Transcript: Q3 2025

Oct 30, 2025, 10:00 AM EDT - 7 months ago

Ventas Earnings Call Transcript: Q3 2025

Ventas Quarterly report: Q3 2025

Oct 30, 2025, 10:00 AM EDT - 7 months ago

Ventas Quarterly report: Q3 2025

Ventas Earnings release: Q3 2025

Oct 30, 2025, 10:00 AM EDT - 7 months ago

Ventas Earnings release: Q3 2025

Ventas Slides: Q3 2025

Oct 30, 2025, 10:00 AM EDT - 7 months ago

Ventas Slides: Q3 2025

Ventas Reports 2025 Third Quarter Results

Oct 29, 2025, 4:10 PM EDT - 7 months ago

Ventas Reports 2025 Third Quarter Results

Ventas Announces Third Quarter 2025 Earnings Release Date and Conference Call

Oct 6, 2025, 4:41 PM EDT - 8 months ago

Ventas Announces Third Quarter 2025 Earnings Release Date and Conference Call

These 15 stocks have beaten the S&P 500 this year — while getting cheaper in the process

Sep 22, 2025, 10:19 AM EDT - 9 months ago

These 15 stocks have beaten the S&P 500 this year — while getting cheaper in the process

ADI BA CCL COIN DASH NUE NVDA

Ventas Transcript: BofA Securities 2025 Global Real Estate Conference

Sep 10, 2025, 3:45 PM EDT - 9 months ago

Ventas Transcript: BofA Securities 2025 Global Real Estate Conference

Ventas Slides: FY 2025

Sep 10, 2025, 3:45 PM EDT - 9 months ago

Ventas Slides: FY 2025

Ventas Provides BofA Securities 2025 Global Real Estate Conference Presentation Materials

Sep 9, 2025, 4:57 PM EDT - 9 months ago

Ventas Provides BofA Securities 2025 Global Real Estate Conference Presentation Materials

Ventas Releases 2024-2025 Corporate Sustainability Report

Sep 8, 2025, 5:00 PM EDT - 9 months ago

Ventas Releases 2024-2025 Corporate Sustainability Report

Ventas to Participate in Investor Meetings at BofA Securities 2025 Global Real Estate Conference

Sep 8, 2025, 4:45 PM EDT - 9 months ago

Ventas to Participate in Investor Meetings at BofA Securities 2025 Global Real Estate Conference

Discovery Senior Living Selected to Operate 15 Ventas-Owned Communities, Expanding Discovery's Portfolio and Strategic Relationship

Aug 8, 2025, 9:02 AM EDT - 10 months ago

Discovery Senior Living Selected to Operate 15 Ventas-Owned Communities, Expanding Discovery's Portfolio and Strategic Relationship

Ventas Earnings Call Transcript: Q2 2025

Jul 31, 2025, 10:00 AM EDT - 11 months ago

Ventas Earnings Call Transcript: Q2 2025

Ventas Quarterly report: Q2 2025

Jul 31, 2025, 10:00 AM EDT - 11 months ago

Ventas Quarterly report: Q2 2025

Ventas Earnings release: Q2 2025

Jul 31, 2025, 10:00 AM EDT - 11 months ago

Ventas Earnings release: Q2 2025

Ventas Slides: Q2 2025

Jul 31, 2025, 10:00 AM EDT - 11 months ago

Ventas Slides: Q2 2025

Healthcare REIT Ventas raises annual FFO forecast on steady demand for senior housing

Jul 30, 2025, 6:09 PM EDT - 11 months ago

Healthcare REIT Ventas raises annual FFO forecast on steady demand for senior housing

Ventas Reports 2025 Second Quarter Results

Jul 30, 2025, 4:10 PM EDT - 11 months ago

Ventas Reports 2025 Second Quarter Results

The Best Growth Stocks to Buy

Jul 8, 2025, 8:12 AM EDT - 11 months ago

The Best Growth Stocks to Buy

ALGM AMZN AVGO BURL CTRE DAR DXCM

Ventas Announces Second Quarter 2025 Earnings Release Date and Conference Call

Jul 7, 2025, 4:20 PM EDT - 11 months ago

Ventas Announces Second Quarter 2025 Earnings Release Date and Conference Call

Final Trades: Amazon, Jefferies Financial, E.L.F. Beauty and Ventas

Jun 6, 2025, 1:33 PM EDT - 1 year ago

Final Trades: Amazon, Jefferies Financial, E.L.F. Beauty and Ventas

AMZN ELF JEF

Ventas Transcript: Nareit REITweek: 2025 Investor Conference

Jun 3, 2025, 1:45 PM EDT - 1 year ago

Ventas Transcript: Nareit REITweek: 2025 Investor Conference

Ventas Issues Business Update and Will Present at Nareit's REITweek 2025 Investor Conference

May 28, 2025, 8:30 AM EDT - 1 year ago

Ventas Issues Business Update and Will Present at Nareit's REITweek 2025 Investor Conference

Ventas Earnings Call Transcript: Q1 2025

May 1, 2025, 10:00 AM EDT - 1 year ago

Ventas Earnings Call Transcript: Q1 2025

Ventas Quarterly report: Q1 2025

May 1, 2025, 10:00 AM EDT - 1 year ago

Ventas Quarterly report: Q1 2025

Ventas Earnings release: Q1 2025

May 1, 2025, 10:00 AM EDT - 1 year ago

Ventas Earnings release: Q1 2025

Ventas Slides: Q1 2025

May 1, 2025, 10:00 AM EDT - 1 year ago

Ventas Slides: Q1 2025

Healthcare REIT Ventas beats quarterly FFO estimates on stable senior housing demand

Apr 30, 2025, 5:56 PM EDT - 1 year ago

Healthcare REIT Ventas beats quarterly FFO estimates on stable senior housing demand

Ventas Reports 2025 First Quarter Results

Apr 30, 2025, 4:10 PM EDT - 1 year ago

Ventas Reports 2025 First Quarter Results

Ventas Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Ventas Proxy statement: Proxy Filing

The Big 3: TJX, VTR, ORCL

Apr 8, 2025, 1:00 PM EDT - 1 year ago

The Big 3: TJX, VTR, ORCL

ORCL TJX

Ventas Announces First Quarter 2025 Earnings Release Date and Conference Call

Apr 4, 2025, 4:18 PM EDT - 1 year ago

Ventas Announces First Quarter 2025 Earnings Release Date and Conference Call

Cramer's Stop Trading: Ventas

Apr 3, 2025, 10:22 AM EDT - 1 year ago

Cramer's Stop Trading: Ventas

Ventas Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Ventas Proxy statement: Proxy Filing

Ventas Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Ventas Proxy statement: Proxy Filing

Ventas Proxy statement: Proxy Filing

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Ventas Proxy statement: Proxy Filing

Ventas Transcript: Citi’s 30th Annual Global Property CEO Conference 2025

Mar 4, 2025, 1:30 PM EST - 1 year ago

Ventas Transcript: Citi’s 30th Annual Global Property CEO Conference 2025

Ventas Slides: FY 2025

Mar 4, 2025, 1:30 PM EST - 1 year ago

Ventas Slides: FY 2025

Ventas to Participate in Investor Meetings at Citi 2025 Global Property CEO Conference

Feb 28, 2025, 4:39 PM EST - 1 year ago

Ventas to Participate in Investor Meetings at Citi 2025 Global Property CEO Conference

Ventas Earnings Call Transcript: Q4 2024

Feb 13, 2025, 10:00 AM EST - 1 year ago

Ventas Earnings Call Transcript: Q4 2024

Ventas Annual report: Q4 2024

Feb 13, 2025, 10:00 AM EST - 1 year ago

Ventas Annual report: Q4 2024

Ventas Earnings release: Q4 2024

Feb 13, 2025, 10:00 AM EST - 1 year ago

Ventas Earnings release: Q4 2024

Ventas Slides: Q4 2024

Feb 13, 2025, 10:00 AM EST - 1 year ago

Ventas Slides: Q4 2024

Healthcare REIT Ventas beats quarterly FFO estimates on senior housing demand

Feb 12, 2025, 5:27 PM EST - 1 year ago

Healthcare REIT Ventas beats quarterly FFO estimates on senior housing demand

Ventas Reports 2024 Full Year Results, Provides 2025 Outlook and Increases Dividend

Feb 12, 2025, 4:10 PM EST - 1 year ago

Ventas Reports 2024 Full Year Results, Provides 2025 Outlook and Increases Dividend

Ventas Announces Tax Treatment Of 2024 Distributions

Jan 21, 2025, 5:38 PM EST - 1 year ago

Ventas Announces Tax Treatment Of 2024 Distributions

Ventas Announces Fourth Quarter 2024 Earnings Release Date and Conference Call

Jan 16, 2025, 4:30 PM EST - 1 year ago

Ventas Announces Fourth Quarter 2024 Earnings Release Date and Conference Call

These 4%+ Yielding ‘Bond Proxies' Are Top Picks For Trump 2.0

Jan 15, 2025, 7:04 AM EST - 1 year ago

These 4%+ Yielding ‘Bond Proxies' Are Top Picks For Trump 2.0

Ventas Reaches Mutually Beneficial Agreements with Brookdale Senior Living

Dec 19, 2024, 6:52 AM EST - 1 year ago

Ventas Reaches Mutually Beneficial Agreements with Brookdale Senior Living

Ventas Declares Fourth Quarter 2024 Dividend of $0.45 Per Common Share

Dec 10, 2024, 4:53 PM EST - 1 year ago

Ventas Declares Fourth Quarter 2024 Dividend of $0.45 Per Common Share

Ventas Comments on Master Lease with Brookdale Senior Living

Dec 3, 2024, 9:16 AM EST - 1 year ago

Ventas Comments on Master Lease with Brookdale Senior Living

Ventas Earns Nareit 2024 Healthcare “Leader in the Light” Award

Nov 20, 2024, 4:30 PM EST - 1 year ago

Ventas Earns Nareit 2024 Healthcare “Leader in the Light” Award

Ventas to Participate in Investor Meetings at Nareit's REITworld 2024 Annual Conference

Nov 15, 2024, 4:14 PM EST - 1 year ago

Ventas to Participate in Investor Meetings at Nareit's REITworld 2024 Annual Conference

Ventas Announces Pricing of an Underwritten Offering of 10.6 Million Shares of Common Stock

Nov 14, 2024, 8:30 AM EST - 1 year ago

Ventas Announces Pricing of an Underwritten Offering of 10.6 Million Shares of Common Stock

Ventas Announces Underwritten Offering of 10.6 Million Shares of Common Stock

Nov 13, 2024, 4:47 PM EST - 1 year ago

Ventas Announces Underwritten Offering of 10.6 Million Shares of Common Stock

Ventas Earnings Call Transcript: Q3 2024

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Ventas Earnings Call Transcript: Q3 2024

Ventas Quarterly report: Q3 2024

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Ventas Quarterly report: Q3 2024

Ventas Earnings release: Q3 2024

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Ventas Earnings release: Q3 2024

Ventas Slides: Q3 2024

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Ventas Slides: Q3 2024

Healthcare REIT Ventas raises annual FFO per share forecast

Oct 30, 2024, 5:43 PM EDT - 1 year ago

Healthcare REIT Ventas raises annual FFO per share forecast

Ventas Reports 2024 Third Quarter Results

Oct 30, 2024, 4:11 PM EDT - 1 year ago

Ventas Reports 2024 Third Quarter Results

Ventas Announces Third Quarter 2024 Earnings Release Date and Conference Call

Oct 4, 2024, 4:14 PM EDT - 1 year ago

Ventas Announces Third Quarter 2024 Earnings Release Date and Conference Call

Ventas Declares Third Quarter 2024 Dividend of $0.45 Per Common Share

Sep 17, 2024, 4:39 PM EDT - 1 year ago

Ventas Declares Third Quarter 2024 Dividend of $0.45 Per Common Share

Ventas Reaches Agreements with Kindred and ScionHealth

Sep 16, 2024, 11:09 AM EDT - 1 year ago

Ventas Reaches Agreements with Kindred and ScionHealth

Ventas Transcript: Bank of America 2024 Global Real Estate Conference

Sep 10, 2024, 4:30 PM EDT - 1 year ago

Ventas Transcript: Bank of America 2024 Global Real Estate Conference

Ventas Slides: FY 2024

Sep 10, 2024, 4:30 PM EDT - 1 year ago

Ventas Slides: FY 2024

Ventas Releases 2023-2024 Corporate Sustainability Report

Sep 9, 2024, 7:45 PM EDT - 1 year ago

Ventas Releases 2023-2024 Corporate Sustainability Report

Bobby_Six_killer
Bobby_Six_killer Jun. 4 at 10:31 PM
$LXRX $NVO $VTR curious why you state "ever expanding sales of inpefa"? 2025 Q1 sales were 1.3 million, while 2026 Q1 sales were 1.1 million. Go back to Q4 2024, net sales were 1.6 million. Are you aware inpefa sales are actually contracting? And you have the audacity to brag in point A, that Inpefa for HCM "is OURS no partnerships". I know you are new to this company, so maybe you aren't aware, but LXRX disbanded their entire sales department in late 2024. So no sales department, they've halted all marketing for Inpefa, so how exactly do you plan to sell if if approved? Hint, it involves finding a partner. And you think drug companies involved with diabetes are going to line up to partner on Sota for T1D after the FDA rejected 3 times already? Take off the rose colored pumper glasses, and realize if pilavapadin fails to meet it's Phase 3 endpoint like it did already for Phase 2, this company is dead in the water.
0 · Reply
SniperPro
SniperPro Jun. 4 at 6:50 PM
$LXRX $NVO $VTR Pretty good summary. HCM still hasn't fully decided yet. I bet they want to test the waters, but they need to stop dealing with the same BS. They need to focus on R&D and selling/partnering assets—nothing else. Collect royalties and keep it simple. Money Money MOneyyyyyyyyy 🤑 🤑 🤑
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jun. 4 at 6:43 PM
$LXRX For those confused on what he said on Pilavapadin Partnership, he said, that big interested parties, came with an offer of large sums, JUST on the Phase 3 results. No need to commit and hang our IP to them until then. Better value for LXRX to hold on to our IP fully, I talked about this before here. It's exactly what he talked about right now. A. HCM will be fully OURS no partnerships. B. Zotagliflozin Type 1 we can partner with many deeply in the Diabetes 1 arena. No other alternative other than insulin for these poor people. C. Novo will dole out another 60 mil by appx on upcoming data from Phase trial studies. They featured it in their last Qtrly $NVO did. D. $VTR will be supplying revenues on an ever expanding sales of Inpefa.
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jun. 3 at 1:07 AM
📊 $VTR Elliott Wave Analysis 🚀 Bullish trend unfolding with upside targets at 104 and beyond — full breakdown available now! 👉 Read here: https://elliottwave-forecast.com/stock-market/ventas-vtr-elliott-wave-analysis-target-104-bullish-trend/ #VTR #ElliottWave #Stocks #Trading #Markets
0 · Reply
PrnceMichael
PrnceMichael Jun. 2 at 4:58 PM
$GOAI #Nasdaq Alert -EVA Live (Nasdaq: GOAI) signed a Letter of Intent with Dermatech Mobile Care, doing business as Spiro Senior Care, for a strategic partnership giving EVA Live a proposed 25% equity stake in the Spiro Senior venture. EVA Live plans to invest up to $20 million in cash, assets and resources to scale Spiro’s AI-driven senior care platform, launched with Meridian Senior Living and its first four senior healthcare facilities, targeting the rapidly growing global geriatric and long-term care markets. https://www.stocktitan.net/news/GOAI/eva-live-targets-the-1-3-trillion-senior-care-industry-through-wkh5mhlcqsh7.html @EvaLiveInc1 @Nasdaq $WELL $VTR
0 · Reply
jbhogan
jbhogan May. 27 at 5:04 PM
$VTR Just mentioned as a buy on CNBC Final Trades. ( Jenny )
0 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 27 at 3:37 AM
📊 $VTR Elliott Wave Analysis 🚀 Bullish trend unfolding with upside targets at 104 and beyond — full breakdown available now! 👉 Read here: https://elliottwave-forecast.com/stock-market/ventas-vtr-elliott-wave-analysis-target-104-bullish-trend/ #VTR #ElliottWave #Stocks #Trading #Markets
0 · Reply
Ares77manoe
Ares77manoe May. 26 at 1:19 PM
$VTR why I sold 3 years ago...
0 · Reply
BillionerOfKing
BillionerOfKing May. 25 at 9:28 PM
$VTR Current Stock Price: $88.18 Contracts to trade: $87.5 VTR Jun 18 2026 Call Entry: $2.20 Exit: $3.65 ROI: 66% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 21 at 2:46 AM
📊 $VTR Elliott Wave Analysis 🚀 Bullish trend unfolding with upside targets at 104 and beyond — full breakdown available now! 👉 Read here: https://elliottwave-forecast.com/stock-market/ventas-vtr-elliott-wave-analysis-target-104-bullish-trend/ #VTR #ElliottWave #Stocks #Trading #Markets
0 · Reply
CapitalMonk
CapitalMonk May. 20 at 4:15 AM
$VTR Price: $88.35 (+0.24%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±2.60% RSI: 55.0 | Momentum: Moderate Volume: -6.9% vs avg Volatility: 1.56% Support: $79.37 | Resistance: $91.06 Sourch: http://marketbaubles.com/
0 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 19 at 1:11 AM
📊 $VTR Elliott Wave Analysis 🚀 Bullish trend unfolding with upside targets at 104 and beyond — full breakdown available now! 👉 Read here: https://elliottwave-forecast.com/stock-market/ventas-vtr-elliott-wave-analysis-target-104-bullish-trend/ #VTR #ElliottWave #Stocks #Trading #Markets
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin May. 17 at 10:09 AM
$VTR Ventas Inc. (NYSE:VTR) is not the loudest stock under $100, but its senior housing momentum, rising FFO guidance, and aging-population tailwind could make this healthcare REIT one of the most interesting long-term real estate plays right now. https://globalmarketbulletin.com/could-ventas-vtr-be-a-smart-healthcare-reit-pick-under-100/
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin May. 17 at 9:49 AM
$ACGL $GH $MCHP $CCI $VTR Not every exciting stock has to trade above $500. These 10 cheap large-cap stocks under $100 include companies with fresh growth stories, improving financial results, AI partnerships, shareholder returns, and sector-specific catalysts that could make them worth watching in today’s stock market. https://globalmarketbulletin.com/top-10-cheap-large-cap-stocks-under-100-to-buy-now/
0 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 15 at 1:28 AM
📊 $VTR Elliott Wave Analysis 🚀 Bullish trend unfolding with upside targets at 104 and beyond — full breakdown available now! 👉 Read here: https://elliottwave-forecast.com/stock-market/ventas-vtr-elliott-wave-analysis-target-104-bullish-trend/ #VTR #ElliottWave #Stocks #Trading #Markets
0 · Reply
NVDAMillionaire
NVDAMillionaire May. 14 at 7:21 AM
$VTR Brilliant piece that captures VTR's situation perfectly. So if you want to update your understanding of VTR or get to know VTR better, this is essential reading. https://everyticker.com/quote/VTR/analysis/ventas-the-shop-transformation-creates-a-senior-housing-compounders-nyse-vtr
0 · Reply
MorganHoratio
MorganHoratio May. 13 at 10:50 PM
All these stocks hit new 52 WEEK HIGHS at some point today Fortinet $FTNT Ormat Technologies $ORA Ventas $VTR Rio Tinto $RIO Air Products $APD This list of 52-week highs maps out the "Resilience Theme" of H1 2026! $FTNT’s breakout suggests a powerful rebound in enterprise cybersecurity spending, while $ORA and $APD prove that "AI’s endgame is Energy & Industrial Gases." Meanwhile, the surge in $RIO and $VTR signals a rotation back into global industrial recovery and defensive yield plays. We are seeing a shift from "Pure AI" to a dual-engine market driven by AI Infra and Macro Recovery. Which of these five do you think has the most "fundamental" staying power, and which is just a momentum play? Any "hidden champions" in your portfolio about to hit new highs? Let’s talk below!
0 · Reply
BillionerOfKing
BillionerOfKing May. 12 at 6:07 PM
$VTR Current Stock Price: $88.76 Contracts to trade: $90.0 VTR May 15 2026 Call Entry: $0.15 Exit: $0.24 ROI: 57% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 8 at 12:51 AM
📊 $VTR Elliott Wave Analysis 🚀 Bullish trend unfolding with upside targets at 104 and beyond — full breakdown available now! 👉 Read here: https://elliottwave-forecast.com/stock-market/ventas-vtr-elliott-wave-analysis-target-104-bullish-trend/ #VTR #ElliottWave #Stocks #Trading #Markets
0 · Reply
ElliottwaveForecast
ElliottwaveForecast May. 6 at 1:04 AM
📊 $VTR Elliott Wave Analysis 🚀 Bullish trend unfolding with upside targets at 104 and beyond — full breakdown available now! 👉 Read here: https://elliottwave-forecast.com/stock-market/ventas-vtr-elliott-wave-analysis-target-104-bullish-trend/ #VTR #ElliottWave #Stocks #Trading #Markets
0 · Reply
CapitalMonk
CapitalMonk May. 4 at 2:19 PM
$VTR Price: $88.14 (+0.14%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.20% RSI: 59.4 | Momentum: Moderate Volume: -93.8% vs avg Volatility: 1.54% Support: $79.37 | Resistance: $88.41 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
Estimize
Estimize May. 4 at 12:00 PM
Wall St is expecting 0.96 EPS for $VTR Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/vtr?chart=historical&metric_name=eps&utm_cont
0 · Reply